Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist

Interv Neuroradiol. 2022 Feb;28(1):84-91. doi: 10.1177/15910199211015038. Epub 2021 May 4.

Abstract

Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.

Keywords: Platelets; aneurysm; hemorrhage; stroke; thrombectomy.

Publication types

  • Review

MeSH terms

  • Humans
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex*

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex